Phibro Animal Health Corporation announced it will pursue patent protection following a significant advance in the ongoing development of an African swine fever (ASF) vaccine.
“ASF’s decimation of China’s swine population represents not just a crisis for the entire swine husbandry industry but, more importantly, a food security crisis for mankind,” said Jack Bendheim, Phibro’s chairman, president and chief executive officer.
According to a company release, this important step in the vaccine development process involves the identification of immunogenic epitopes and proteins that show strong potential to form the basis for a vaccine against ASF.
Using a unique bioinformatics analysis tool, Phibro’s R&D team and its collaborators made this discovery, allowing them to select for the highest potential epitopes and proteins capable of eliciting protective immune response.
Phibro said their approach is to create a specific epitope-based vaccine, rather than following the more conventional path of an attenuated live vaccine.
If successful, Phibro said this approach would not only be an effective response to ASF but would result in a vaccine that presents no risk of further spreading the disease.
“The identification of this group of peptides and proteins is a key milestone in Phibro’s pursuit of a solution for this devastating disease,” Bendheim said. “While we still have much work ahead of us, we have made important progress toward reaching that goal and we take pride in potentially being part of the solution to such an urgent problem.”
ASF is a deadly virus that impacts pigs, but poses no threat to humans and is not a food safety risk. For more on the spread of ASF worldwide, visit porkbusiness.com/ASF.
More from Farm Journal's PORK: